Schwab Andrew J. sold $880K of CAMP (indirect holdings)
Schwab Andrew J. sold 191,865 indirectly-held shares of Camp4 Therapeutics Corp (CAMP) at an average of $4.59 ($4.50–$4.76, $0.88M total) across 3 trades over 2026-08-19 to 2026-08-21.
How this was made
The 30-second read
Why it matters
The insider sale provides fresh data on insider sentiment, which can affect short‑term price dynamics.
Market read
First‑report Form 4 filing; modest size but may influence trader sentiment on CAMP.
What to watch
No 10b5‑1 plan; the director may be diversifying holdings.
Background
Camp4 Therapeutics Corp is a clinical‑stage biotech focused on rare diseases.
Ticker impact
Director Andrew J. Schwab sold 191,865 shares for $879,718, reducing his stake to 2,433,280 shares.
Possible short-term downside pressure as market absorbs the insider sell.
Form 4 is a primary source; the transaction size is modest for a micro‑cap, but insider sales often trigger sell‑offs.
Market effects
Minimal impact on the broader biotech sector.
Limited to U.S. OTC/OTC market participants.
None
Counterpoint
The sale could be a routine liquidity move, not a negative signal.
Key entities
- CompanyCamp4 Therapeutics Corp
Biotech issuer of ticker CAMP.
- DirectorAndrew J. Schwab
Insider who sold shares.